Scilex Holding Company’s Ongoing Legal Battle with Aveva Drug Delivery Systems
On March 26, 2025, Scilex Holding Company (Nasdaq: SCLX), a leading company in the non-opioid pain management sector, announced that it has appealed a lower court decision to the U.S. Court of Appeals for the Federal Circuit in Washington, D.C. The Company reiterated its commitment to vigorously pursuing its infringement action against Aveva Drug Delivery Systems, Inc. (Aveva) on appeal.
Background of the Dispute
Scilex Holding Company, based in Palo Alto, California, specializes in acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company has also recently proposed a joint venture with IPMC Company to focus on neurodegenerative and cardiometabolic diseases.
Aveva Drug Delivery Systems, headquartered in New Jersey, is a leading provider of drug delivery systems and technologies. Scilex accused Aveva of infringing on its patents related to its non-opioid pain management product, Ztare-HC (hydrocodone capsules). The lower court ruled in favor of Aveva, but Scilex is not backing down.
Impact on Scilex
The loss in the lower court was a significant setback for Scilex. However, the Company remains optimistic about the outcome of the appeal. Scilex believes that Aveva’s drug delivery technology used in its products infringes on its intellectual property. The Company’s persistence in pursuing this legal action underscores its commitment to protecting its intellectual property and maintaining its competitive edge in the market.
Impact on the World
The outcome of this legal battle could have far-reaching implications for the pharmaceutical industry, particularly in the non-opioid pain management sector. If Scilex is successful in its appeal, it could set a precedent for other companies to protect their intellectual property more aggressively. On the other hand, if Aveva is found not to have infringed on Scilex’s patents, it could send a message that patent protection in the industry is not as strong as some companies may believe.
Conclusion
Scilex Holding Company’s decision to appeal the lower court decision in its infringement action against Aveva Drug Delivery Systems demonstrates the Company’s unwavering commitment to protecting its intellectual property and maintaining its competitive edge in the non-opioid pain management sector. The outcome of this legal battle could have significant implications for the pharmaceutical industry as a whole, and the world will be watching closely to see how it unfolds.
- Scilex Holding Company is appealing a lower court decision in its infringement action against Aveva Drug Delivery Systems.
- The Company believes Aveva’s drug delivery technology infringes on its intellectual property.
- The outcome of this legal battle could have far-reaching implications for the pharmaceutical industry.
